1. Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity
- Author
-
Ahmet Kucukarda, Irfan Cicin, Musa Baris Aykan, Sezin Sayın, Nuri Karadurmus, and Ali Gökyer
- Subjects
0301 basic medicine ,Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Immunology ,Antineoplastic Agents ,Antibodies, Monoclonal, Humanized ,03 medical and health sciences ,0302 clinical medicine ,Atezolizumab ,Female patient ,Immunology and Allergy ,Medicine ,Humans ,Carcinoma, Renal Cell ,Immune Checkpoint Inhibitors ,Pneumonitis ,Osteosarcoma ,business.industry ,Pneumothorax ,Immunotherapy ,medicine.disease ,Kidney Neoplasms ,respiratory tract diseases ,surgical procedures, operative ,030104 developmental biology ,Nivolumab ,Oncology ,030220 oncology & carcinogenesis ,Metastatic osteosarcoma ,Female ,Radiology ,business ,Tomography, X-Ray Computed ,After treatment - Abstract
Background: We present two cases of secondary pneumothorax after immunotherapy in two different clinics. Case summary: A 25-year old female patient with metastatic osteosarcoma, treated with atezolizumab. Grade 2 pneumonitis developed twice in the first year. Treatment was continued after recovery and areas of pneumonitis and pneumothorax were observed on computed tomography. No other reason could be found to cause pneumothorax. Pneumothorax resorbed spontaneously during follow-up. A 36-year old female patient treated with nivolumab for metastatic renal cell carcinoma (RCC), areas of pneumonitis and pneumothorax were only found as the cause of dyspnea. After treatment, remission was achieved on computed tomography findings. Pneumothorax was detected for the second time during continued therapy, and immunotherapy stopped permanently. Conclusion: These cases, indicate that immunotherapy can cause secondary immune-related pneumothorax based on immune pneumonitis.
- Published
- 2021